Jyong Biotech Ltd. (MENS)
NasdaqGM · USD · Healthcare · Biotechnology
$1.91 (+5.52%) as of
Key statistics
- Market cap
- 145.21M
- EPS (TTM)
- -0.0600
- Dividend yield
- 0.00%
- 52-week range
- 1.4300 – 52.0100
- Profit margin
- 0.00%
- Volume
- 19.85k
About Jyong Biotech Ltd.
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New Taipei City, Taiwan
- Employees
- 27
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.